International news in seven languages
The FDA has approved the first drug that directly targets Alexander disease, a devastating neurological disorder affecting fewer than one in a million people. Developed through decades of research, Zanvastro showed promising results in clinical trials, stabilizing motor function and even improving movement in some patients.
The FDA has approved the first drug that directly targets Alexander disease, a devastating neurological disorder affecting fewer than one in a million people. Developed through decades of research, Zanvastro showed promising results in clinical trials, stabilizing motor function and even improving movement in some patients.
